KP1019: Difference between revisions
CSV import |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 25: | Line 25: | ||
[[Category:Clinical trials]] | [[Category:Clinical trials]] | ||
{{pharmacology-stub}} | {{pharmacology-stub}} | ||
= KP1019 Transferrin = | |||
<gallery> | |||
File:HSA.1AO6.jpg | |||
</gallery> | |||
Latest revision as of 03:22, 17 February 2025
KP1019 is a anticancer drug that belongs to the class of ruthenium(III) complexes. It is also known as Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] and has been studied for its potential use in the treatment of various types of cancer.
Chemistry[edit]
KP1019 is a ruthenium complex, which means it is a compound that contains ruthenium and is coordinated to several ligands. In the case of KP1019, these ligands are two indazole molecules and four chloride ions. The ruthenium atom is in the +3 oxidation state.
Mechanism of Action[edit]
The exact mechanism of action of KP1019 is not fully understood. However, it is believed to interact with DNA, causing damage and leading to cell death. It may also inhibit the activity of topoisomerase II, an enzyme that is involved in DNA replication and repair.
Clinical Trials[edit]
KP1019 has been tested in phase I clinical trials for the treatment of advanced solid tumors. The results showed that the drug was well tolerated and had some anticancer activity. However, further studies are needed to confirm these findings and to determine the optimal dosing regimen.
Side Effects[edit]
As with all anticancer drugs, KP1019 can cause side effects. These may include nausea, vomiting, fatigue, and anemia. However, the severity of these side effects can vary greatly from person to person.
See Also[edit]
References[edit]
<references />
